Pharma news
Pharma
Trademark activity surged across major markets in 2024 | Swiss pharma ranks among top foreign portfolios in US, UK and EU | Mainland China is largest filer worldwide despite dip in applications | Several major life sciences companies held strong US trademark portfolios. 15 May 2025
Americas
Counsel are using their unique position as the centre of science and law to deliver value far beyond traditional IP protection, finds Marisa Woutersen. 9 May 2025
Americas
Wilson Sonsini, Desmarais, and Wolf Greenfield were among the winners at the inaugural LSPN Awards USA 2025 in Boston, which celebrated excellence in life sciences IP across 20 categories. 8 May 2025
Americas
Legal heads from Pfizer and The Broad Institute stress the need for cross-disciplinary teams and careful training as AI software becomes mainstream, reports Marisa Woutersen from LSPN 2025. 8 May 2025
Americas
In just 100 days, the Trump administration has issued a record-breaking 90 executive orders—triggering operational uncertainty, staffing upheaval, and growing delays at the US Patent and Trademark Office, hears Marisa Woutersen at LSPN in Boston. 7 May 2025
Americas
The ‘Wands factors’ are extending patent litigation—allowing functionally defined claims to survive longer than expected, hears Marisa Woutersen in Boston. 6 May 2025
Americas
The pharma giant and biopharma company Incyte announce settlement of dispute over alleged unpaid royalties | News comes on eve of trial in Manhattan. 6 May 2025
Americas
Latest report highlights increasing concerns over counterfeit pharmaceuticals, IP barriers, and market access challenges | Key countries to watch include India, China, the UAE, and Singapore | Report also outlines challenges in Mexico, Russia, Brazil, and Indonesia. 1 May 2025
Americas
Duo behind Comirnaty fails to convince Delaware judge to dismiss Alnylam patent claims on grounds of invalidity. 1 May 2025
Europe
EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an injunction against Glenmark’s diabetes generic | AstraZeneca intends to appeal. 29 April 2025